globalgrindamedstore

Bad cholesterol, beware! globalgrinda pharmaceuticals is hot on your trail. The biopharmaceutical company develops cholesterol-lowering drugs for the treatment of cardiovascular and metabolic disease, specifically targeting elevated ldl (low-density lipoprotein, also known as "bad" cholesterol) levels. Aegerion's first approved drug is juxtapid (lomitapide, branded lojuxta in europe), a protein inhibitor that blocks cholesterol production in the liver and intestine. The firm is working on getting juxtapid approved in japan and for children and teens. Aegerion also markets myalept, a treatment for leptin deficiency. Aegerion plans to merge with canada's qlt to create novelion therapeutics.

† some telephone numbers on the hoover’s site may be on a country’s do not call or do not contact list including, but not limited to, the united kingdom’s ctps or tps registers. It is a legal requirement that companies do not make sales or marketing calls to registered numbers. These are central opt out registers whereby corporate subscribers and individuals can register their preference not to receive unsolicited sales and marketing telephone calls. By using the information provided on the hoover’s sites, as the direct marketer you represent and warrant that you will use such information in compliance with all applicable local, state, national or international laws and regulations, including any local do not call registers or marketing regulations, and agree to defend, indemnify and hold harmless dun & bradstreet and each of its affiliates in the event your use violates such laws and regulations